Ex-Pfizer facility has successful pre-approval inspection

CMO Pillar5, selected by IntelGenx to manufacture its high-strength CPI-300 bupropion hydrochloride antidepressant, has passed its FDA pre-approval inspection with no Form 483 being issued. The agency visited Pillar5's Arnprior, Ontario manufacturing facility, a former Pfizer plant that dates from 1956. Pillar5 moved in in 2009 and employs about 100. IntelGenx release

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.